High response rates and safe toxic profile of brentuximab vedotin/bendamustine combination in heavily pretreated patients with relapsed/refractory H odgkin lymphoma ( HL )
Wannesson, B., Remaggi, G., Intile, D., Ferrari, L., Cruset, S., Fernández, I., Miodosky, M., Cugliari, M.S., Bordone, J., Pavlovsky, M.A.
Published in Hematological oncology (01.06.2017)
Published in Hematological oncology (01.06.2017)
Get full text
Journal Article
High response rates and safe toxic profile of brentuximab vedotin/bendamustine combination in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma (HL)
Wannesson, B., Remaggi, G., Intile, D., Ferrari, L., Cruset, S., Fernández, I., Miodosky, M., Cugliari, M.S., Bordone, J., Pavlovsky, M.A.
Published in Hematological oncology (01.06.2017)
Published in Hematological oncology (01.06.2017)
Get full text
Journal Article